tbuckley/cabot-search huggingface dataset:
Abstract 500: Efficacy of UVC irradiation on GFP-expressing melanoma growth and vascularity in the ear of nude mice
Authors: Ryoichi Aki, Yasuyuki Amoh, Hiroyuki Kishimoto, Hiroaki Kimura, Atsushi Suetsugu, Masashi Momiyama, Kensei Katsuoka, Robert M. Hoffman
Journal: Cancer Research (2010)

Abstract Our laboratory has developed the use of fluorescent proteins for in vivo imaging (Nature Reviews Cancer 5, 796-806, 2005). We have developed melanoma cell lines that stably express GFP and nude mice that ubiquitously express RFP to study tumor interaction by dual-color imaging. In the present study, we examined the efficacy of UVC irradiation on the growth of murine melanoma expressing GFP in the ear of GFP mice. We also evaluated the efficacy of UVC irradiation against blood vessels vascularizing the melanoma. RFP-expressing blood vessels from transgenic mice expressing RFP used as hosts were readily visible in GFP melanoma. B16F10 melanoma expressing GFP were injected subcutaneously in the ear of the RFP mice. The ears of the mice were observed before and 24 hours after irradiation with UVC. UVC was effective on B16F10 GFP growth and also damaged blood vessels in the tumor. Thus, UVC irradiation has a direct effect on melanoma growth as well as an anti-angiogenesis effect. This dual-color tumor-host model is useful for evaluation of efficacy on melanoma growth and tumor blood vessels, which is readily discernable with fluorescent protein imaging. UVC irradiation is a promising therapeutic for melanoma expressing fluorescent proteins which can be effected in vivo (Proc. Natl. Acad. Sci. USA, 1-6, 14514-14517, 2009). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 500.
Abstract 2160: Development of selective MELK kinase inhibitors for cancer treatments.
Authors: Piotr Kowalczyk, Paulina Wegrzyn, Przemyslaw Zawadzki, Edyta Palacz, Ewa Trebacz, Katarzyna Wiklik, Mariusz Milik, Adrian Zarebski, Karolina Krawczynska, Krzysztof Brzózka
Journal: Cancer Research (2013)

Abstract Maternal embryonic leucine zipper kinase (MELK) is an atypical member of the AMPK family of serine-threonine kinases that has been implicated in stem cell renewal, cell cycle progression, cytokinesis, mRNA splicing and apoptosis. MELK activity is correlated with its phosphorylation level, is cell cycle dependent and maximal during mitosis although direct upstream regulators of MELK kinase activity are unknown. This kinase is highly expressed in several types of solid cancers: colon, breast, ovary, lung, and brain and shows relatively low expression levels in normal tissues. MELK overexpression in patient-derived tumors strongly correlates with poor prognosis in glioblastoma and breast cancer. Moreover, siRNA mediated knockdown of MELK kinase significantly inhibits growth of tumor cell lines both in vitro and in vivo. Therefore, MELK kinase is an emerging and interesting target of significant potential for therapeutic intervention in cancer. In this study, we are reporting results for a series of new MELK kinase inhibitors that were developed at Selvita. Newly synthesized derivatives exert good selectivity and potency in MELK inhibitions with the low sub-micromolar range. Anticancer effects of these compounds were investigated in several cancer cell lines of solid tumor origin where the compounds were shown to induce cell death with low micromolar ED50 values. Compounds were also analyzed for their effects on cell death, proliferation, apoptosis, cell cycle parameters and ADME properties. Taken altogether, the presented data supports our rationale of using inhibitors of MELK kinases as a novel approach for the cancer therapy, especially for the treatment of glioblastoma and breast cancer. Citation Format: Piotr Kowalczyk, Paulina Wegrzyn, Przemyslaw Zawadzki, Edyta Palacz, Ewa Trebacz, Katarzyna Wiklik, Mariusz Milik, Adrian Zarebski, Karolina Krawczynska, Krzysztof Brzózka. Development of selective MELK kinase inhibitors for cancer treatments. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2160. doi:10.1158/1538-7445.AM2013-2160
GW25-e1103 Clinical risk factors and early onset of maternally inherited essential hypertension
Authors: Chen Xi, Zhang Yusong, Lan Yunfeng, Li Xiaoqi, Wang Xuyun, Liu Yuqi, Yang Jie, Li Zongbin, Gao Jinliao, Li Yang, Yin Tong
Journal: Journal of the American College of Cardiology (2014)
AB0290 Drug survival rates of anti-tumor necrosis factor therapies in patients with rheumatoid arthritis
Authors: S.-S. Lee, K.-E. Lee, D.-J. Park
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To investigate the drug survival of anti-tumor necrosis factor (TNF) agents in Korean patients with rheumatoid arthritis (RA) and find potential predictors associated with treatment discontinuation. <h3>Methods</h3> This study included 114 RA patients who were treated with anti-TNF agents in a single tertiary center for at least one year from December 2005 to November 2010. Demographic, clinical, laboratory, and treatment-related data, and DAS28 score at the time of initiation of anti-TNF agents were collected, and the cause of discontinuation was also obtained by reviewing patients’ charts. Survival curves were plotted to compare the drug survival between three different anti-TNF agents, and multivariate Cox proportional hazard models were used to assess predictors of treatment discontinuation of anti-TNF therapy. <h3>Results</h3> Of the 114 patients, 22 patients received infiliximab, 39 etaneercept, and 48 adalimumab. Over a mean follow-up of 33.8 months (range, 10–77 months), 64patients (56.1%) discontinued their first anti-TNF agents. The mean duration of receiving the first anti-TNF agents was 18.1 months, and 1-year and 4-year drug survival rates were 44% and 37%, respectively. In multivariate Cox proportional hazard analyses, the drug discontinuation rate was differed between the 3 anti-TNF agents (p&lt;0.05). The etanercept group had a lower discontinuation rate compared with the infliximab group (hazard ratio [HR] 0.472, 95% CI 0.230-0.976, p&lt;0.05). The discontinuatoin rate between the adalimumab group and the infliximab group was not different. Patients receiving corticosteroids in combination with anti-TNF agents were more likely to discontinue their anti-TNF therapies (HR 7.850, 95% CI 1.012-60.890, p&lt;0.05). The most common reason for discontinuation of anti-TNF agents was inefficacy (67.2%): 70.6% with etanercept, 64.3% with adalimumab, and 68.4% with infliximab. Other discontinuation causes were infection (5 patients), skin eruption (3 patients), and aggravation of heart failure (1 patient). <h3>Conclusions</h3> The drug survival rate of anti-TNF agents was relatively lower in these patients, with etanercept having the best retention rate. The predictor of discontinuation of anti-TNF therapy was the concomitant use of corticosteroids. Our study provides further evidence that the real-life treatment of RA patients may be different from that of randomized clinical trials. <h3>Disclosure of Interest</h3> None Declared
Survival and Causes of Death in Cirrhotic and in Noncirrhotic Patients with Primary Hemochromatosis
Authors: Claus Niederau, Rudolf Fischer, Amnon Sonnenberg, Wolfgang Stremmel, Hans J. Trampisch, Georg Strohmeyer
Journal: New England Journal of Medicine (1985)

We analyzed survival and causes of death among 163 patients with primary hemochromatosis diagnosed between 1959 and 1983. The mean follow-up period was 10.5 +/- 5.6 years (+/- S.D.). Cumulative survival was 92 per cent at 5 years, 76 per cent at 10 years, 59 per cent at 15 years, and 49 per cent at 20 years. Life expectancy was reduced in patients with cirrhosis of the liver as compared with those without cirrhosis (P less than or equal to 0.05), in patients with diabetes mellitus as compared with those without diabetes (P less than or equal to 0.002), and in patients who could not be depleted of iron during the first 18 months of venesection therapy as compared with those who could be depleted (P less than or equal to 0.001). Prognosis was not influenced by sex (P less than or equal to 0.5). Patients without cirrhosis had a life expectancy that was not different from that expected in an age- and sex-matched normal population. Analysis of the causes of death in 53 patients, as compared with the normal population, showed that liver cancer was 219 times more frequent among the patients (16 patients), cardiomyopathy was 306 times more frequent (3 patients), liver cirrhosis was 13 times more frequent (10 patients), and diabetes mellitus was 7 times more frequent (3 patients). Death rates for other causes, including extrahepatic carcinomas (seven patients), were not different from the rates expected. We conclude that patients with hemochromatosis diagnosed in the precirrhotic stage and treated by venesection have a normal life expectancy, whereas cirrhotic patients have a shortened life expectancy and a high risk of liver cancer even when complete iron depletion has been achieved.
The Influence of Mode of Presentation on the Pattern of Recurrence in Early Breast Cancer (EBC).
Authors: J. Mansell, W. Angerson, C. Wilson, J. Doughty
Journal: Cancer Research (2009)

Abstract IntroductionAn early peak in recurrence exists in women with EBC. This may be explained underlying tumour biology or a reaction to surgery. Screen detection has been shown to have a prognostic effect independent of disease stage suggesting a connection with underlying tumour biology. We aim to determine if the pattern of recurrence differs between modes of presentation.MethodsData from 3 centres in Glasgow of consecutive women aged between 50-65yrs with early stage breast cancer (EBC) diagnosed between 1995 and 2001 were examined. Recurrence was defined as invasive disease at any site. Patients were grouped by mode of presentation into screen detection and symptomatic. Kaplan Meier and time dependent Cox analysis were performed.Results1534 women were included with a median follow up of 5.5yrs. Mode of presentation was screening in 1007 (65.6%) women. At 2.5yrs cumulative recurrence was 2.5% (95% CI 1.5-3.5) in the screen detected group and 9.7% (7.2-12.2) in the symptomatic group. At five years the corresponding rates were 7.8% (6.0-9.6) vs. 19.1% (15.6-22.6). Time dependent multivariate analysis showed that the difference in the risk of recurrence between the modes of presentation was significantly different within 2.5yrs from diagnosis compared with later than 2.5yrs (p = 0.019). The hazard ratio for recurrence within 2.5 yrs was 0.59 (95% CI 0.34-1.00, p=0.05) and after 2.5yrs was 1.23 (0.84-1.80, p =0.285).ConclusionsThese results suggest that women with screen detected cancers have a better prognosis initially following diagnosis independent of disease stage. However this additional benefit isn't maintained with longer follow up. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3056.
AB1415 Telephonic rheumatologist nurse consulting: 1 year time experience
Authors: M.J. Sáiz, J.I. Cortés, M.F. Marilla, I.D.L.M. Barrio, C.M.F. Olmos, D.Y. García, E.V. Pascual, M.R. Villarino, A.M. Ferrer, J.J.A. Sancho, V.C. Tarin
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> In January 2011, at our centre, we started a Rheumatology nurse-led telephone clinic, in order to monitor drugs toxicity and evolution of disease in patients with good disease control and on stable treatment. <h3>Objectives</h3> To describe the nurse-led telephone clinic activity in a Rheumatology Service, and its influence on the decrease of welfare load and safety of drugs management. <h3>Methods</h3> Descriptive retrospective study, collecting the nurse-led telephonic clinic between January 27th and December 30th 2011. This clinic was performed 3 days a week by one nurse with a computer with access to the clinical history and laboratory results, and an external telephone. The protocolized data collected included: duration of the call, necessity of doctor involvement and doctor visit, drug monitoring and diagnosis. <h3>Results</h3> A total of 978 telephone consultations were carried out for 414 patients. The diagnosis distribution was Rheumatoid Arthritis 45.2% (187), Osteoporosis 18.6% (77), Psoriatic Arthritis 13.1% (54), Ankylosing Spondylitis 9.7% (40), other Spondyloarthropaties 7.7% (32), Paget Disease 1.4% (6), SLE 1.2% (5), Polymyalgia Rheumatica 1.2% (5), and others 1.9% (8). The distribution of monitored drugs was Methotrexate 61% (597), Zoledronic Acid 14.7% (144), Leflunomide 10% (97), Sulfasalazine 5.9% (58), and others 15% (147). The duration of calls was fewer than 10 minutes in 91.5% (895) of the cases. Only in 8.7% (85) was consultation with a doctor necessary, with a doctor’s visit required in 30% (25) of them. In regards to inflammatory systemic diseases, this strategy allows saving 834 visits with a doctor. <h3>Conclusions</h3> Creating a nurse-led telephone clinic in Rheumatology allows the avoidance of unnecessary hospital visits, benefiting both patients and doctors. <h3>Disclosure of Interest</h3> None Declared
Moderate T1-201 Chloride Uptake in Cerebral Infarction
Authors: J Wijaya, E Bernard, P Roach, N Little
Journal: Clinical Nuclear Medicine (2001)

WIJAYA, JOHAN M.B.B.S., F.R.A.C.P.*; BERNARD, ELIZABETH M.B.B.S., F.R.A.C.P., D.D.U.*; ROACH, PAUL M.B.B.S., F.R.A.C.P.*; LITTLE, NICKOLAS M.B.B.S., F.R.A.C.S.† Author Information
Abstract 1249: The role of ATM-dependent Chk2 activation on post-transcriptional gene regulation by RNA-binding protein, HuR: implications for lymphoma development in AT patients
Authors: Krystyna Mazan-Mamczarz, Patrick Hagner, Bojie Dai, Zhenqiu Liu, Ronald B. Gartenhaus
Journal: Cancer Research (2010)

Abstract Maintenance of genomic stability depends on the DNA damage response a biological tumorigenesis barrier in early stages of cancer development. In response to DNA double strand breaks, ATM phosphorylates multiple proteins involved in both cell cycle checkpoints and DNA repair including the checkpoint kinase Chk2. The human disease ataxia-telangiectasia (AT) in which the ATM gene is deleted or inactivated is characterized by progressive neurodegeneration, immunodeficiency and genomic instability. AT patients show a hypersensitivity to radiotherapy and an extraordinary high risk of developing pediatric lymphomas. Recently it was reported that Chk2 interacts and phosphorylates the RNA-binding protein HuR, leading to alteration of it RNA-binding ability. HuR is a key post-transcriptional regulator of genes involved in stress response, cell cycle, immunoresponse, tumorigenesis, and senescence. To gain a better understanding of the complexity of the ATM/Chk2/HuR regulatory pathway we investigated the influence of ATM/Chk2 signaling on HuR binding activity in the DNA damage response by global microarray examination of mRNAs associated with HuR in response to ionizing radiation (IR) in both ATM wild type and ATM null lymphocytes. Importantly, pharmacological inhibition either ATM or Chk2 proteins, or knockdown of Chk2 expression using RNA interference, reduced the HuR-mRNA association with a number of validated target genes. Mutation of Chk2 phosphorylated residues in HuR suggests Ser100 site to be important for increased association and Thr118 dissociation of HuR-mRNA complexes after IR. Our data demonstrated that low dose (1Gy) of IR activates the ATM signaling cascade, but not ATR pathway, resulting in the sequential phosphorylation of Chk2 and HuR, subsequently modulating the association of HuR with target mRNAs and thereby regulating these gene's expression. Functional network analysis revealed signaling pathways, which are frequently deregulated in lymphoid malignancies to be predominantly represented by transcripts differentially associated with HuR after exposure to IR in ATM wild type compared to ATM null lymphocytes. A better understanding of the mechanism and affected species of mRNA could help to develop more effective targeted treatments in ATM null patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1249.
F-18 FDG PET/CT Findings in a Case of Spinal Cord Sarcoidosis
Authors: Kazuyoshi Suga, Naofumi Matsunaga, Kawakami Yasuhiko, Naofumi Matsunaga, Norihiro Seki, Hideo Kataoka, Toshihiko Taguchi
Journal: Clinical Nuclear Medicine (2011)

We describe FDG PET/CT findings in a rare case of histologically proven cervical spinal cord sarcoidosis (SCS) which mimics spinal cord myelopathies or tumors on magnetic resonance imaging. FDG PET/CT showed coexistence of FDG-avid cervical cord focus and intrathoracic lymphadenopathies. Corticosteroid therapy showed rapid improvement of this patient's SCS-related neurologic symptoms, and disappearance of the hypermetabolic cervical cord focus and lung lymphadenopathies on follow-up FDG PET/CT scan, regardless of still-remained cervical cord lesion on magnetic resonance imaging. FDG PET/CT appears helpful for establishing the diagnosis of SCS in cases with FDG-avid intrathoracic lymphadenopathies and for early evaluation of response to treatment.
Abstract 3941: Altered helical structures: Repair and induction of genomic instability
Authors: Faye A. Rogers
Journal: Cancer Research (2010)

Abstract Naturally occurring DNA sequences capable of forming H-DNA (triplexes) are found in the human genome as frequently as 1 in every 50,000 base pairs. These sequences, typically located in promoters and exons have been found to be intrinsically mutagenic and are believed to be involved in the regulation of expression of several cancer-linked genes. To counteract the potentially devastating effects of altered helical structures on genomic integrity, an intricate balance between DNA repair and apoptosis is critical. In the present work, we have investigated the potential for non-canonical structures to trigger pro-apoptotic pathways. In conjunction with the use of a fibroblast line containing multiple chromosomal target sites, sequence-specific triplex-forming oligonucleotides (TFOs) were used to synthetically create altered helical structures. Our studies demonstrate that DNA damage induced by these structures can trigger the switch from DNA repair to apoptosis. Additional studies were initiated to determine whether key proteins that contributed to cellular survival by participating in the repair of helical distortions also played a role in triggering the cell to activate a pro-apoptotic pathway. The TFIIH factor, XPD has been implicated in our studies to occupy a central role in triggering apoptosis in response to excessive H-DNA induced damage. Knock-down of XPD resulted in a significant decrease in H-DNA induced apoptosis, thus suggesting that key proteins that contribute to cellular survival by acting in DNA repair become executioners in the face of excess DNA damage. The maintenance of this mechanism may be of central importance for avoiding progression to cancer, because the default mechanism of apoptosis prevents expansion of cells in which unrepaired damage would lead to mutation and carcinogenesis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3941.
Diagnostic Dilemma: Lymphocele With Features of a Urinary Leak
Authors: EUGENE LIN, SYDNEY HEYMAN
Journal: Clinical Nuclear Medicine (1997)

A 16-year-old boy presented with edema and inflammation of the right lower quadrant anterior abdominal wall and increasing abdominal girth at 4 weeks after cadaveric renal transplant for familial nephritis. An ultrasound was performed, which showed a large fluid collection adjacent to the transplant kidney. There was a question as to whether this represented a lymphocele or urinoma. A Tc99m DTPA renal scan, abdominal CT scan, and cystogram were performed to establish the diagnosis.
Huge Primary Soft Tissue Sarcoma of the Breast on Bone Scan
Authors: Yeh-You Shen, Yu-Chin Wu, Chia-Hung Kao, Te-Chun Hsieh
Journal: Clinical Nuclear Medicine (2013)

A 54-year-old woman had a primary breast sarcoma with rapid enlargement in 3 months. The mass became so huge that it was more than 20 cm in diameter and occupied the entire right breast on presentation. Extraosseous uptake was present in this mass and demonstrated a unique picture, mimicking the posture of a racing driver who holds a helmet under the armpit, on the bone scan.
PTH-150 Benefits of a Liver Transplant Outreach Clinic: Increased Referrals and Patient Satisfaction: Abstract PTH-150 Table 1
Authors: J L Hulley, A Douglass, S White, S Masson
Journal: Gut (2013)

<h3>Introduction</h3> The current landscape of service provision for patients with liver disease does not match that of disease burden<sup>1</sup>. Most hepatologists are based in transplant centres and access to tertiary liver services is not geographically equitable<sup>1</sup>. In an attempt to improve access, we established a liver transplant outreach clinic from the regional liver unit within a large gastroenterology unit. Here, we describe the benefits of this clinic. <h3>Methods</h3> A dedicated monthly joint liver clinic was established in a large gastroenterology unit. Patients with complex liver disease, including pre- and post-transplant are seen by a consultant transplant hepatologist from the regional liver unit (SM) and a local consultant gastroenterologist (AD). Quantitative data was available from the transplant centre. A sample of patients and specialists were asked to complete a written questionnaire on their opinions of the clinic service. <h3>Results</h3> Since August 2010, over 400 patients have been seen. In the 4 years prior to the establishment of the clinic, there were a median of 3 (1–4) referrals annually for liver transplant assessment. This increased to 9.5 (9–10) in the subsequent 2 years. Patients were satisfied with the clinical service (Table 1) and the majority (95%) preferred local follow up, citing it as more convenient (100%) with easier travel arrangements (100%). Specialists (n = 16) agreed unanimously that the clinic was more convenient for patients, easy to refer into and improved both accessibility to liver services and communication with the regional liver unit. Most (83%) felt that it reduced waiting times for specialist opinion. <h3>Conclusion</h3> Establishing an outreach clinic has increased referrals for transplant assessment. Patients prefer to be seen locally and do not feel this affects their specialist care. They have confidence in the skill and experience of the clinicians they see and rate the quality of care, highly. Referring clinicians are also satisfied with the quality and accessibility of the outreach clinic. Overall, outreach clinics may serve to improve equity of access to transplant services. <h3>Disclosure of Interest</h3> None Declared. <h3>Reference</h3> Liver Disease Patient Landscape and Care Provision, 2011, http://www.liver.nhs.uk/publications/accessed 14th Jan 2013